Date: 2015-01-29
Type of information: Licensing agreement
Compound: Hepatitis B vaccine candidates in combination with adjuvant IC31®
Company: Valneva (France) Immune Targeting Systems (UK)
Therapeutic area: Infectious diseases
Type agreement: development licensing commercialisation
Action mechanism: adjuvant/vaccine. IC31® is a synthetic adjuvant combining the immunostimulating properties of an 11-mer antimicrobial peptide (KLK) and a synthetic oligodeoxynucleotide (ODN1a) which is a Toll-like receptor 9 agonist without containing cytosine phosphate guanine (CpG) motifs. Eight human clinical trials have shown IC31® to be a safe and immunogenic adjuvant in study volunteers. Those receiving IC31® have reported good local tolerance with no systemic adverse effects reported during clinical studies.
Disease: hepatitis B
Details: * On January 29, 2015, Valneva and UK company Immune Targeting Systems (ITS) announced that they have signed an exclusive worldwide commercial license agreement. The agreement grants Immune Targeting Systems the rights to research, develop and commercialize Hepatitis B vaccine candidates in combination with Valneva’s IC31® Adjuvant. Immune Targeting Systems focused on the development of T-cell vaccines to highly mutated viruses and to cancers utilizing its proprietary long-peptide based Depovaccine® platform. The company is supported by Novartis Venture Fund, HealthCap, Truffle Capital, Esperante Ventures and London SME.
Financial terms: Financial terms of the agreement were not disclosed but include an upfront payment. If successful, product candidates from these agreements may lead to additional cash payments for achieved milestones along with future royalties on net sales.
Latest news:
